(Q37833906)

24 August 2017

1 reference

title

Lipid parameters for measuring risk of cardiovascular disease (English)

1 reference

24 August 2017

cardiovascular disease

1 reference

3

John J P Kastelein

1 reference

24 August 2017

Benoit J Arsenault

1

1 reference

24 August 2017

S Matthijs Boekholdt

series ordinal

2

1 reference

24 August 2017

language of work or name

English

0 references

publication date

1 February 2011

1 reference

Nature Reviews Cardiology

24 August 2017

1 reference

24 August 2017

8

1 reference

24 August 2017

4

1 reference

24 August 2017

197-206

1 reference

https://scigraph.springernature.com/pub.10.1038/nrcardio.2010.223

24 August 2017

0 references

cites work

Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.223

Receptor-Mediated Control of Cholesterol Metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.223

Hypolipidemic effects in monkeys of ML-236B, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.223

Competitive inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase by ML-236A and ML-236B fungal metabolites, having hypocholesterolemic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.223

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.223

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.223

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.223

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.223

Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.223

Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.223

Global burden of cardiovascular diseases: Part II: variations in cardiovascular disease by specific ethnic groups and geographic regions and prevention strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.223

Prevalence of overweight and obesity in the United States, 1999-2004

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.223

A potential decline in life expectancy in the United States in the 21st century

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.223

Comparing trends in BMI and waist circumference

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.223

The role of adipose tissue dysfunction in the pathogenesis of obesity-related insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.223

Abdominal obesity and metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.223

Mechanisms linking obesity with cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.223

Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.223

Disease prevention--should we target obesity or sedentary lifestyle?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.223

Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.223

Prediction of Coronary Heart Disease Using Risk Factor Categories

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.223

Are you targeting non-high-density lipoprotein cholesterol?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.223

Beyond low-density lipoprotein cholesterol: respective contributions of non-high-density lipoprotein cholesterol levels, triglycerides, and the total cholesterol/high-density lipoprotein cholesterol ratio to coronary heart disease risk in apparently

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.223

Triglycerides and the Risk of Coronary Heart Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.223

Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.223

Major lipids, apolipoproteins, and risk of vascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.223

Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.223

Total cholesterol/HDL cholesterol ratio vs LDL cholesterol/HDL cholesterol ratio as indices of ischemic heart disease risk in men: the Quebec Cardiovascular Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.223

Usefulness of the triglyceride-high-density lipoprotein versus the cholesterol-high-density lipoprotein ratio for predicting insulin resistance and cardiometabolic risk (from the Framingham Offspring Cohort)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.223

Clinical Utility of Different Lipid Measures for Prediction of Coronary Heart Disease in Men and Women

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.223

Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.223

Refining lipoprotein assessment in diabetes: apolipoprotein B makes sense

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.223

Cholesterol levels in small LDL particles predict the risk of coronary heart disease in the EPIC-Norfolk prospective population study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.223

Association of coronary atherosclerosis with hyperapobetalipoproteinemia [increased protein but normal cholesterol levels in human plasma low density (beta) lipoproteins]

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.223

Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.223

ApoB versus non-HDL-C: what to do when they disagree

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.223

Antiinflammatory properties of HDL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.223

Are apolipoproteins better discriminators than lipids for atherosclerosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.223

Apolipoprotein A-I and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the Québec cardiovascular study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.223

High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.223

The joint effects of apolipoprotein B, apolipoprotein A1, LDL cholesterol, and HDL cholesterol on risk: 3510 cases of acute myocardial infarction and 9805 controls

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.223

Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.223

Apolipoproteins A-I, A-II and B, lipoprotein(a) and the risk of ischaemic heart disease: the Caerphilly study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.223

Role of the apolipoprotein B-apolipoprotein A-I ratio in cardiovascular risk assessment: a case-control analysis in EPIC-Norfolk

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.223

Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.223

Value of low-density lipoprotein particle number and size as predictors of coronary artery disease in apparently healthy men and women: the EPIC-Norfolk Prospective Population Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.223

LDL particle subclasses, LDL particle size, and carotid atherosclerosis in the Multi-Ethnic Study of Atherosclerosis (MESA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.223

Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.223

High-density lipoprotein particle size and concentration and coronary risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.223

Lipid assessment, metabolic syndrome and coronary heart disease risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.223

HDL particle size and the risk of coronary heart disease in apparently healthy men and women: the EPIC-Norfolk prospective population study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.223

Comparison between gradient gel electrophoresis and nuclear magnetic resonance spectroscopy in estimating coronary heart disease risk associated with LDL and HDL particle size

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.223

VAP II analysis of lipoprotein subclasses in mixed hyperlipidemic patients on treatment with ezetimibe/simvastatin and fenofibrate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.223

The effect of simvastatin on triglyceride-rich lipoproteins in patients with type 2 diabetic dyslipidemia: a SILHOUETTE trial sub-study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.223

Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.223

Apolipoprotein(a) isoforms and the risk of vascular disease: systematic review of 40 studies involving 58,000 participants

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.223

Genetic variants associated with Lp(a) lipoprotein level and coronary disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.223

Genetically elevated lipoprotein(a) and increased risk of myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.223

Lipoprotein(a) as a cardiovascular risk factor: current status

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.223

Phospholipase A(2) in vascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.223

Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.223

Inflammation in atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.223

NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.223

C-reactive protein and cardiovascular risk: more fuel to the fire

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.223

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.223

C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.223

Genetic Loci associated with C-reactive protein levels and risk of coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.223

The association of C-reactive protein and CRP genotype with coronary heart disease: findings from five studies with 4,610 cases amongst 18,637 participants

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.223

Genetically elevated C-reactive protein and ischemic vascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.223

C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds Risk Score for men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.223

Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.223

C-reactive protein and risk of cardiovascular disease in men and women from the Framingham Heart Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.223

C-reactive protein modulates risk prediction based on the Framingham Score: implications for future risk assessment: results from a large cohort study in southern Germany

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.223

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.223

Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.223

Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.223

Relationship between lipid levels and clinical outcomes in the Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Trial: to what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.223

Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.223

Apolipoproteins, cardiovascular risk and statin response in type 2 diabetes: the Collaborative Atorvastatin Diabetes Study (CARDS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.223

Prognostic utility of apoB/AI, total cholesterol/HDL, non-HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes: results from PROVE IT-TIMI 22.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.223

Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.223

Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.223

Ability of traditional lipid ratios and apolipoprotein ratios to predict cardiovascular risk in people with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.223

Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.223

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.223

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.223

HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.223

Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.223

Targets for LDL-lowering therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.223

Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.223

Apolipoprotein B and cardiovascular disease risk: position statement from the AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.223

2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.223

C-Reactive Protein and Prediction of Coronary Heart Disease and Global Vascular Events in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.223

The Epidemiology of Cardiovascular Diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.223

RISK FACTORS IN CORONARY HEART DISEASE. AN EVALUATION OF SEVERAL SERUM LIPIDS AS PREDICTORS OF CORONARY HEART DISEASE; THE FRAMINGHAM STUDY

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.223

Some factors associated with the development of coronary heart disease: six years' follow-up experience in the Framingham study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.223

Population trends in the incidence and outcomes of acute myocardial infarction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.223

Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.223

Nonfasting Triglycerides and Risk of Myocardial Infarction, Ischemic Heart Disease, and Death in Men and Women

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.223

Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Québec Cardiovascular Study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.223

Inflammatory biomarkers, physical activity, waist circumference, and risk of future coronary heart disease in healthy men and women

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.223

Visceral Fat Adipokine Secretion Is Associated With Systemic Inflammation in Obese Humans

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.223

Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.223

Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.223

Quantification of plasma lipoproteins by proton nuclear magnetic resonance spectroscopy.

31 March 2020

1 reference

12 December 2020

Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report

1 reference

12 December 2020

Study design and rationale for the clinical outcomes of the STABILITY Trial (STabilization of Atherosclerotic plaque By Initiation of darapLadIb TherapY) comparing darapladib versus placebo in patients with coronary heart disease

1 reference

12 December 2020

Quantification of cholesterol in all lipoprotein classes by the VAP-II method

1 reference

12 December 2020

Cholesterol and lipids in the risk of coronary artery disease--the Framingham Heart Study

1 reference

12 December 2020

The recent decline in mortality from coronary heart disease, 1980-1990. The effect of secular trends in risk factors and treatment

1 reference

12 December 2020

10.1038/NRCARDIO.2010.223

Identifiers

DOI

1 reference

Dimensions Publication ID

24 August 2017

0 references

1 reference